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Modeling signaling in breast cancer <p>Mapping of sub-networks in the EGFR-MAPK pathway in different breast cancer cell lines reveals that PAK1 may be a marker for sen- sitivity to MEK inhibitors.</p>
Abstract
Background: Cancer is a heterogeneous disease resulting from the accumulation of genetic
defects that negatively impact control of cell division, motility, adhesion and apoptosis.
Deregulation in signaling along the EgfR-MAPK pathway is common in breast cancer, though the
manner in which deregulation occurs varies between both individuals and cancer subtypes.
Results: We were interested in identifying subnetworks within the EgfR-MAPK pathway that are
similarly deregulated across subsets of breast cancers. To that end, we mapped genomic,
transcriptional and proteomic profiles for 30 breast cancer cell lines onto a curated Pathway Logic
symbolic systems model of EgfR-MAPK signaling. This model was composed of 539 molecular
states and 396 rules governing signaling between active states. We analyzed these models and
identified several subtype-specific subnetworks, including one that suggested Pak1 is particularly
important in regulating the MAPK cascade when it is over-expressed. We hypothesized that Pak1
over-expressing cell lines would have increased sensitivity to Mek inhibitors. We tested this
experimentally by measuring quantitative responses of 20 breast cancer cell lines to three Mek
inhibitors. We found that Pak1 over-expressing luminal breast cancer cell lines are significantly
more sensitive to Mek inhibition compared to those that express Pak1 at low levels. This indicates
that Pak1 over-expression may be a useful clinical marker to identify patient populations that may
be sensitive to Mek inhibitors.
Conclusions: All together, our results support the utility of symbolic system biology models for
identification of therapeutic approaches that will be effective against breast cancer subsets.
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Background
Cancer is a heterogeneous disease that results from the accu-
mulation of multiple genetic and epigenetic defects [1-4].
These defects lead to deregulation in cell signaling and, ulti-
mately, impact control of cell division, motility, adhesion and
apoptosis [5]. The mitogen-activated protein kinase (MAPK)/
Erk pathway plays a central role in cell communication: it
orchestrates signaling from external receptors to internal
transcriptional machinery, which leads to changes in pheno-
type [6,7]. This pathway has been implicated in the origin of
multiple carcinomas, including those of the breast [8-10].
Activation of MAPK is initiated by one of the four ErbB recep-
tors (ErbB1/epidermal growth factor receptor (EgfR), ErbB2-
4), which leads to signaling through Raf (RAF proto-onco-
gene serine/threonine-protein kinase), Mek (mitogen-acti-
vated protein kinase kinase 1/2) and Erk. In addition, the
ErbB receptors integrate a diverse array of signals, both at the
cell surface level and through cross-talk with other pathways,
such as the phosphoinositide 3-kinase (Pi3k) pathway [11].
Both EgfR and ErbB2 are overexpressed in a substantial frac-
tion of breast cancers and are recognized targets for breast
cancer therapy [12-16]. In addition, Mek has long been stud-
ied as a therapeutic target, and many drugs that inhibit it are
currently under development [17-20].
Among breast cancers, unique subsets can be defined at the
genomic, transcriptional and proteomic levels. For many
years, breast cancers were classified by whether or not they
express various receptors, namely the estrogen receptor (ER/
EsR1), the progesterone receptor (PR/PGR) and ErbB2 [21-
25]. This key insight has been used to tailor therapies to indi-
vidual patients [22,26]. Of particular interest is the finding
that ER-negative tumors frequently show elevated signaling
along the MAPK pathway compared to ER-positive cancers
[27]. DNA amplification at various loci can also be used to
stratify patients, and, importantly, has prognostic value as
well [28,29]. For example, amplification at 8p12 and 17q12
are both associated with poor outcome [28,30]. The emer-
gence of expression profiling technology led to the seminal
observation that breast cancers can be systematically classi-
fied at the transcriptional level [23-25]. More recently, inter-
est has turned toward the analysis of somatic mutations [31].
Different cancer types show common patterns of mutation,
implying that a few key mutations play a pivotal role in tum-
origenesis. All together, these studies indicate the value of
identifying unique subsets of cancers, both for understanding
the origin of the disease as well as identification of appropri-
ate therapeutics.
A critical question remaining is how to identify meaningful
subsets of cancers that differ in their cell signaling pathways.
One approach to this problem is to identify gene expression
signatures that reflect the activation status of oncogenic path-
ways [32,33]. While it is possible to stratify cancers into
unique populations based on their expression patterns of
these signatures, a key challenge lies in interpreting the
meaning of the various genes within these signatures [34].
Here, we used an alternative approach in which we explored
subtype-dependent behavior in genes that make up known
signaling pathways.
Our goal was to identify signaling pathway modules that are
deregulated in particular cancer subtypes. To that end, we
populated a well-curated cell signaling model with molecular
information from a panel of breast cancer cell lines. We used
a combination of transcriptional, proteomic and mutational
data to create a unique signaling network for each cell line.
Specifically, we discretized transcript and protein data and
used them to populate the network models; genes or proteins
that are differentially expressed across the cell lines were
evaluated as present in some cell lines and absent from oth-
ers. The resultant network models can be viewed as a statisti-
cal formalism of the pathways activated in each of the cell
lines.
We created our network models with Pathway Logic [35-38],
a system designed to build discrete, logical (rule-based) mod-
els of signal transduction pathways [39]. Logical models are
directly related to the canonical schematic diagrams ('car-
toons') commonly used to show functional relationships
among proteins, and, as such, are easily interpretable in the
context of biological systems (Figure 1b) [40]. The two critical
elements of a Pathway Logic model are a rule set and an initial
state. The rules represent biochemical reactions, and the ini-
tial state is a representation of all proteins present in a partic-
ular cell line. Our model contains a rich rule set: the
interactions between proteins have all been individually
curated from primary literature sources and, therefore repre-
sent well-characterized signaling biology. In short, we used
our collection of molecular data to identify active states in
each cell line, and the rules to define signaling between these
active states. The resultant networks are static coarse graphi-
cal representations of signaling that can be used to generate
hypotheses about key signaling events in subsets of the cell
lines.
We focused our modeling on the ErbB/MAPK pathway
because deregulation along this pathway is both frequent in
breast cancers and heterogeneous across them [12,41]. Fur-
ther, it is involved in a complex web of signaling that results
from cross-talk with other pathways [42]. Our model system
includes rules that describe: interactions between the ErbB
receptors and their ligands; direct association of intracellular
signaling proteins with phosphorylated ErbB receptors; sign-
aling along the canonical Raf-Mek-Erk pathway; cross-talk
with Pi3k and Jak/Stat pathways; activation of immediate-
early transcription factors (for example, Jun and Fos); and
signaling from other receptors that influence MAPK signal-
ing, including EphA2 (Ephrin type-A receptor 2 precursor)
and integrins.http://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.3
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Our panel of cell lines captures many features of biological
variation found in primary breast tumors [43]. Both the cell
lines and tumors cluster into basal (EsR1-negative, Caveolin-
1 (Cav1)-positive) and luminal (EsR1-positive, ErbB3-posi-
tive) expression subsets. These two subtypes - basal and lumi-
nal - also show distinct biological characteristics, including
differences in morphology and invasive potential [23,25]. In
addition, the cell lines show a broad response to pathway-tar-
geted drugs (Gray et al., unpublished data). Overall, the
genomic heterogeneity in the cell lines mirrors that observed
in a large population of primary tumors, and as an ensemble
constitutes a useful model of the molecular diversity of pri-
mary tumors [43].
We generated signaling network models for our panel of cell
lines with the goal of identifying subnetworks that are active
in particular subsets of cell lines. We found that the discre-
tized data used to populate the initial states of the networks
showed only a small amount of variation. Specifically, only
13% of the components in the initial state of the networks var-
ied across the cell lines. Even with this small amount of vari-
ation, the discretized data used in the initial states could be
clustered into basal and luminal cell line groups. Surprisingly,
over half of the protein interactions predicted to occur varied
across the cell line network models. In order to identify active
subnetworks, we clustered the network features of our mod-
els, which resulted in three main groups of cell lines: basal,
luminal and a third mixed group composed of both basal and
The signaling networks include several hundred components, all connected in a discrete manner Figure 1
The signaling networks include several hundred components, all connected in a discrete manner. (a) Example network. Each circle represents a 
component in the network; lines represent connections between them (that is, rules). Key signaling components are noted. (b) A small subnetwork. (c-e) 
Examples of data used to populate the model. Each histogram shows the distribution of expression values across the complete panel of cell lines. Data for 
each component in the model were clustered individually to determine whether or not the component should be included in the initial state. Components 
that clustered into two groups were present in the initial states of some cell lines and absent from others. (c) Raf1 transcript data yields a single group. (d) 
ErbB4 protein data yields two groups. (e) EsR1 yields three groups.
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luminal cell lines. In addition, we identified several network
modules active in specific subsets of the cell lines. One mod-
ule in particular implicated Pak1 (p21 protein (Cdc42/Rac)-
activated kinase 1) as a key regulator of the Raf-Mek-Erk
pathway in the subset of Pak1 over-expressing cell lines. We
found that among luminal cell lines, the over-expression of
Pak1 was significantly associated with sensitivity to Mek inhi-
bition. Taken together, these results indicate that our mode-
ling approach can be used to identify signaling subnetworks
that are particularly important in subsets of breast cancer cell
lines.
Results
Data clustering and model initialization
Our goal was to create a unique signaling network model for
each cell line in our panel. In generating these models, we
must accommodate two fundamental biological principles.
First, the ErbB network results from the integration of many
diverse signals, and second, most cell signaling occurs
through protein-protein interactions. Ideally, then, we would
create large networks populated with protein data. However,
the acquisition of comprehensive protein abundance data for
multiple cell lines is not technically feasible, so we used tran-
script data to infer protein levels when protein data were una-
vailable. An example of one of these large computed networks
is shown in Figure 1a.
A key feature of Pathway Logic models is that they are dis-
crete, so components are considered either present or absent.
In order to populate our network models, we first discretized
the transcript and protein data (see Materials and methods;
Figure 1c-e). Following discretization, we determined which
components (proteins) were present in the initial state of each
cell line. We considered genes and proteins that are differen-
tially expressed across the cell lines to be present in some cell
lines and absent from others. Genes and proteins that showed
little variation in expression were considered present in all
cell lines. Although this approach is coarse, we can use it to
assess which pathways may be most critical in each of the cell
lines. That is, we can identify the pathways that may be highly
up- or down-regulated in particular cell lines. This discretiza-
tion algorithm captured many well-documented differences
in expression across the cell lines. For example, the transcript
data for EsR1 yields three clusters, which parallels the obser-
vation that primary breast tumors show varied expression of
this protein (Figure 1e) [44,45].
The initial states were constructed from a population of 286
signaling components. We had expression data alone for 191
of these components, both protein and expression data for 25,
and no available data for the 70 remaining components. Fol-
lowing discretization, 13 out of 25 (52%) proteins and 19 out
of 191 (10%) transcripts form both present and absent groups.
For the remaining protein and transcript data, a single group
best describes the distribution of expression values. To
explore the transcript and protein data further, we compared
the clustering results for the 25 components that had both
protein and transcript data available. Approximately two-
thirds of these components show a high level of concordance
between the two discretized datasets: nine yield a single
present group for both datasets; eight yield a present and
absent group for both datasets (mean Pearson's r = 0.603).
The remaining eight components form a single group in one
dataset and two groups in the other. For six of these, the tran-
script data yield a single group while the protein data form
two groups (Table 1).
We used the Sanger COSMIC database to identify mutations
to Kras (Transforming protein p21 K-Ras 2/Ki-Ras/c-K-ras),
Pten (Phosphatidylinositol-3,4,5-trisphosphate 3-phos-
phatase) and Pik3ca (PI3-kinase p110 subunit alpha) in our
cell lines, and included these data in the initial states [46]. We
focused on mutations in these three proteins for two reasons:
first, they influence MAPK signaling, and second, the muta-
tions have a known functional impact, so it is possible to com-
putationally model them. Specifically, a G13D point mutation
in Kras causes it to become constitutively active [47,48]. A
Table 1
Comparison of discretized protein and transcript data
Protein clusters Transcript clusters Pearson's correlation
Irs1 2 2 0.0354
EgfR 2 2 0.491
ErbB3 2 2 0.491
Cav1 2 2 0.523
CD44 2 2 0.6
Cav2 2 2 0.882
EsR1 2 2 0.883
Cdh1 2 2 0.923
Akt1 1 1 -
Grb2 1 1 -
Hras 1 1 -
Igf1R 1 1 -
Jak1 1 1 -
Kras 1 1 -
MAPK1 1 1 -
MAPK3 1 1 -
Ptk2 1 1 -
ErbB2 1 2 -
Grb7 1 2 -
CtnnB1 2 1 -
Efna1 2 1 -
ErbB4 2 1 -
Rela 2 1 -
Src 2 1 -
Jun 2 1 -http://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.5
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frameshift mutation in Pten leads to premature termination
and an inactive protein [49]. Three common point mutations
in Pik3ca (E542K, E545K and H1047R) lead to increased lipid
kinase activity [50,51]. Pik3ca is the most frequently mutated
gene in our cell line panel (6 of 30; 20%), a finding that par-
allels other reports [52].
Initial states reflect the known biology
We found that 39 out of 286 (13%) of the components vary
across the initial states of the cell lines (Figure 2). This
includes both the effect of data discretization, as well as dif-
ferences in mutational status for Kras, Pten and Pik3ca. The
components that vary are located throughout the network
and include receptors, GTPases and transcription factors. We
used unsupervised hierarchical clustering to analyze the var-
iable components in the initial states [53]. In accordance with
our previous studies, we found that the site of origin, basal or
luminal epithelium, largely defines the two major clusters
[43]. We achieved a similar result when we clustered the data
with a partitioning around medoids (PAM) algorithm that
searched for two groups in the discretized data. Specifically,
most of the cell lines (26 out of 30) correctly segregated into
basal or luminal groups. This finding demonstrates that our
modeling system has some of the genes that influence this
phenotypic difference. Further, it indicates that the discre-
tized data used to populate the network models recapitulate
some of the known cell biology associated with the origins of
the breast cancer cell lines.
The network models are highly variable
A principal interest in modeling these pathways was to deter-
mine how network topology differs across the set of cell lines.
To address this question, we determined which components
and rules were present in each of the networks. The network
models contain an average of 334 (8.29 standard error of the
mean) rules and 218 (4.55 standard error of the mean) unique
state changes. Over 55% of the rules and state changes differ
across the 30 models, indicating that the networks are highly
variable (Table 2). This result was surprising at first, consid-
ering that the initial states have 87% of the components in
common.
To explore this finding further, we examined the connectivity
of individual components by determining the number of rules
in which each component is involved. The majority of the
components participate in only one or two rules, whereas a
few components participate in many rules (Figure 3a). EgfR,
the most highly connected component, is involved in 22 rules.
When we plotted these data on a log-log plot, a robust linear
relationship was revealed, indicating that the connectivity fol-
lows a power-law (Figure 3b). Interestingly, some of the most
highly connected components vary across the initial states of
the cell lines, namely EgfR, Src, Pi3k, and Kras (Table 3).
These proteins have a particularly large role in shaping net-
work topology. If they are omitted from the initial state, many
rules will fail to fire and many pathways in the resultant net-
work will be truncated.
We were interested in whether the cell line models could be
grouped by their network properties. We addressed this by
performing an unsupervised hierarchical clustering of the
network features (that is, the components in the initial state,
rules, and components that underwent state changes) that
differed across the cell lines. This clustering resulted in three
major groups for the cell line models: basal, luminal and a
third group composed of both basal and luminal cell lines
(Figure 4). The observation that there is a mixed group of
basal and luminal networks indicates that the cell lines may
be segmented by their signaling pathways, rather than by site
of origin alone.
Initial states recapitulate the known biology Figure 2
Initial states recapitulate the known biology. Heatmap shows the 
components in the initial states that varied across the cell lines. Each 
column represents the initial state from a single cell line network; each 
row represents data for one component. Red indicates the component is 
present in the cell line model; green indicates it is absent. Data are 
hierarchically clustered along both dimensions. Basal and luminal cell lines 
cluster into distinct groups.
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Unique signaling modules are active in particular 
subsets of the network models
We next asked how the network structure varies across the
cell lines. To answer this question, we used PAM clustering to
partition the network features into 30 clusters. Each cluster
represents a unique 'signaling module' that is present in some
cell line models and absent from others. A summary of these
signaling modules provides an overview of the variable net-
work features (Table 4). Each signaling module is driven by
the presence of particular components in the initial state. For
example, the ErbB4 module is present in ten cell lines, nine of
which are luminal and one that is basal, reflecting the fact that
ErbB4 is present in the initial state of these ten cell lines. The
signaling modules average eight rules each, though they vary
in siz e fr om a sin g le r u le u p to  7 6 r ul es  f or th e  Sr c/ R ac1
module.
The RhoB (ras homolog gene family, member B) module is
largely responsible for the segmentation of the basal and
luminal cell line models, and is present in all the luminals and
absent from all the basals. RhoB interacts with NGEF
(Ephexin, EPH receptor interacting exchange protein) to acti-
vate many downstream targets that go on to regulate a diverse
array of cellular functions, including cell motility, cell adhe-
sion and cell cycle progression [54,55]. RhoB levels have been
shown to decrease as cancer progresses [56-58]. In accord-
ance with this, we have found that the basal cell lines are far
more invasive than the luminal cell lines [43].
Clustering of the 'mixed' group of cell lines is strongly driven
by the three Src modules (Figure 4). Src is one of the most
highly connected components in the network (18 rules), and
serves to integrate a variety of signals. This module, which
results from the omission of Src from the initial state, is
present in all cell lines except two, basaloid MDAMB435 and
luminal MDAMB453. The other two Src modules are depend-
ent on the presence of either EgfR or Rac1. The Src/EgfR
module includes Src-dependent activation of EgfR; if either
component is missing from the initial state, signaling along
this cascade is compromised. The Src/EgfR module is absent
only from the mixed group of networks: four are missing
EgfR, one is missing Src, and the other is missing both EgfR
and Src.
One small signaling module is related to the presence of Cav1
in the initial state. One of the rules in this module describes
activation of Shc that is dependent on Fyn (Proto-oncogene
tyrosine-protein kinase Fyn), Cav1 and Integrin (ITGB1)
(Figure 5a). Both the transcript and protein data indicate that
the presence of Cav1 is bimodal, and is clearly present at
either very low or very high levels (Figure 5b,c). This module
is only present in basal cell lines, and, further, most of the cell
lines that contain it are of the most aggressive basal B subtype
[43]. This signaling module provides a direct feed into the
Raf-Mek-Erk pathway, suggesting that these cell lines have an
alternative route available for Erk activation (Figure 5a). This
interaction may help to explain why these basal cell lines are
particularly aggressive.
Pak1 plays a pivotal role in the network models
In our model, Pak1 is required for the activation of Mek and
Erk (Figure 6a). Specifically, Pak1 phosphorylates Mek, which
in turn facilitates signaling along the Raf-Mek-Erk cascade
[59]. It follows, then, that network models with Pak1 omitted
from the initial state fail to activate Erk. Across the cell lines,
the distribution of Pak1 transcript levels is highly skewed, so
our discretization algorithm yields two clusters, a large group
centered at -0.26, and a small group centered at 2.16 (Figure
6b). Pak1 is present in the initial state of the cell lines with
high expression and absent from the others. The four cell
lines with high Pak1 transcript levels, MDAMB134, 600MPE,
SUM52PE and SUM44PE, are all of luminal origin.
Based on the observations that Pak1 directly regulates MAPK
signaling, and that its expression pattern shows substantial
variation in breast cancers, we hypothesized that Pak1 differ-
entially regulates MAPK signaling across our panel of cell
lines. We tested this hypothesis experimentally. The first
issue we addressed was whether Pak1 protein levels vary
across the cell lines. We found highly variable expression of
total Pak1 protein. Specifically, three of the four cell lines with
elevated Pak1 transcript levels have concordantly high Pak1
protein levels. In addition, a handful of other cell lines also
show over-expression of Pak1 protein. Pak1 transcript and
protein levels are significantly correlated (Pearson's r = 0.78,
P  < 0.0001; Figure 6c). While this relationship is largely
dependent on the cell lines that highly express Pak1, it none-
theless supports the idea that elevated transcript levels affect
protein expression levels. Focal changes in copy number are
thought to convey a selective advantage for tumor growth, so
we next asked whether Pak1 is amplified in any of our cell
lines. The four cell lines that over-express Pak1 show high-
level amplification (>8.7 copies; see Materials and methods)
of the Pak1 amplicon (11q13.5-q14 [60]; Figure 6d); none of
the other cell lines show this amplification. In addition to
Pak1 amplification, three of these cell lines also show amplifi-
cation at CCND1, though in all cases there are distinct peaks
at each locus.
If Pak1 indeed regulates MAPK signaling, we would expect to
find a correlation between Pak1 and phospho-Mek levels. To
address this, we quantified isoform-specific phospho-Mek
Table 2
Summary of network features for the cell line models
Total Number variant Percent variant
Rules 396 248 60
State changes 253 141 55
Initial state 286 39 13http://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.7
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levels in our cell lines (see Materials and methods). We found
a small but significant correlation between total Pak1 and per-
cent Mek1-S298 (Pearson's r = 0.32, P < 0.05; Figure 6e).
Although the correlation is somewhat weak, it is clear that
high Pak1 levels are always associated with elevated phospho-
Mek1. In accordance with the observation that the interaction
between Pak1 and Mek is specific to Mek1 [61], we found no
correlation between Pak1 and percent phospho-Mek2 (P>>
0.05).
The above findings suggest that elevated Pak1 levels provide a
foothold into regulation of the MAPK cascade, and led us to
hypothesize that Pak1 over-expressing luminal cell lines
would be particularly sensitive to Mek inhibition. To test this,
we measured the response of 20 luminal cell lines to three
Mek inhibitors: CI-1040, UO126 and GSK1120212. We com-
pared growth inhibition (GI50, the drug concentration
required to inhibit growth by 50%) following drug exposure
between cell lines that over-express Pak1 (n = 3) and those
that do not (n = 17). The two groups of cell lines had signifi-
cantly different mean expression of both the Pak1 transcript
and protein (t-test, P < 0.01). The three Pak1 over-expressing
cell lines (MDAMB134, SUM52PE and 600MPE) were signif-
icantly more sensitive to Mek inhibition compared to the non-
Pak1 over-expressing cell lines (GSK1120212, P < 0.005; CI-
1040, P < 0.05; UO126, P < 0.05; t-test; Figure 7). This result
indicates that Pak1 over-expression may be a useful clinical
marker to determine whether a particular tumor will be
responsive to Mek inhibition.
Discussion
Cancer arises from deregulation in any of a multitude of
genes, but exactly how this deregulation impacts cell signal-
ing is not well understood. Here, we leveraged a rich dataset
of transcriptional and protein profiles with a computational
modeling system in order to gain a greater understanding of
the critical signaling pathways associated with breast cancer.
By creating a unique network model for individual cell lines,
we were able to identify signaling pathways that are particu-
larly important in subsets of the cell lines. Our modeling led
to new insight about the importance of Pak1 as a modulator of
the MAPK cascade.
Approaches to computational modeling
There are many approaches to computationally modeling bio-
logical systems, ranging from high-level statistical models to
low-level kinetic models [62]. We used a simplified mid-level
scheme to construct network models from transcript and pro-
tein profiles for two reasons. First, we were able to create a
unique model for each cell line, rather than a single network
that represents 'breast cancer.' We used this approach to
examine how a collection of genomic and proteomic changes
in individual cell lines affects its network architecture. In con-
trast, other approaches, such as Bayesian reconstruction, are
designed to describe ensemble behavior, rather than behavior
of individual cell lines [63,64]. A key attribute of our mode-
ling system is that it can be used to identify specific biological
instances of cell signaling that can be used to generate
hypotheses. Our observations about Pak1 are a key example of
Table 3
The most highly connected components in the network model
Component Number of rule connections Variable across initial state
EgfR 22 Yes
Pi3k 20 Yes
Src 18 Yes
Kras 17 Yes
RhoB 17 Yes
RhoA 17 No
Cbl 16 No
Cdc42 16 No
Rac1 16 No
Erk1 15 No
Erk2 15 No
Hras 14 No
Grb2 13 No
PIP2 13 No
Raf1 13 No
Smad2 12 No
Acta1 11 No
EphA2 11 No
Pkca 11 Nohttp://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.8
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this feature. The second reason for using this mid-level mod-
eling scheme is that the computational algorithm is relatively
simple; logical operators define relationships between signal-
ing components. It is therefore possible to create networks
that are quite large, which provides the opportunity to exam-
ine multiple inputs that impinge upon the central signaling
pathway of interest. In comparison, kinetic models that offer
more detail about signaling components are quite computa-
tionally demanding, so it is only feasible to examine a limited
number of components [65,66]. As a 'hypothesis generator,'
our modeling system could be used to guide the development
of dynamic modeling systems by identifying key signaling
components to include in them.
One limitation of our modeling system is that it operates in a
totally discrete manner: components are either present or
absent, and rules fire with absolute certainty or not at all. This
is a simplification of true biological systems in which the lev-
els of signaling components show a wide dynamic range, and
the probability that a reaction will occur changes as a function
of the concentration of individual proteins. We captured the
variation in the concentration of signaling components by
individually discretizing the data for each component in the
initial state and then assigning each cell line to a 'present' or
'absent' group. With this approach, we examined how signal-
ing is affected by extreme changes in protein levels, therefore
homing in on key signaling events. We found that even with
this simplified approach, we were able to make insights into
key signaling events in subsets of our cell lines. Hybrid mod-
eling approaches, which combine continuous dynamical sys-
tems with discrete transition systems, have been developed to
overcome this limitation [67,68]. Modification of the current
model system to a hybrid system would allow for a more
detailed examination of cell signaling over smaller changes in
protein concentrations.
Modeling results
We found that the network connectivity follows a power law
relationship in which most components have low connectivity
while a few components are highly connected (Figure 3). The
relationship we observed reflects not only intrinsic connectiv-
Network connectivity follows a power-law relationship Figure 3
Network connectivity follows a power-law relationship. (a) Distribution 
of the number of rule connections for each component in the model. Most 
components have only a few rule connections. (b) Log-log plot. Each dot 
represents the number of components in the model that have a particular 
number of rule connections. The line represents the least-squares fit to 
the data.
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The network models cluster into basal, luminal and mixed groups of cell  lines Figure 4
The network models cluster into basal, luminal and mixed groups of cell 
lines. Heatmap shows the network features that varied across the cell line 
network models. Each column represents data from one network model; 
each row represents data for one network feature (component in the 
initial state, rule or component that underwent a state-change). Red 
indicates the component is present in the cell line; green indicates it is 
absent. Hierarchical clustering along the vertical dimension reveals that the 
networks form basal, luminal and mixed clusters. Hierarchical clustering 
along the horizontal dimension yields 30 signaling modules, each of which 
represents a small subnetwork. Signaling modules of particular interest, 
along with the key components in the initial state, are noted along the 
right side.
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ity, but also curation bias, as literature relevant to EgfR/
MAPK signaling was preferentially surveyed during creation
of the rule set. Nonetheless, this 'scale free' relationship has
been described in more thorough surveys of protein-protein
interactions [69,70]. The observation that our network mod-
els have this scale free property supports the idea that they are
biologically relevant representations. Further, this pattern of
connectivity implies that the few highly connected compo-
nents may be most critical for regulating cell signaling along
these pathways - these components serve as promising candi-
dates for more detailed study at both the computational and
experimental levels. Those that also show substantial varia-
tion across the cell lines (for example, EgfR, Src, Pi3k, and
Kras) may be particularly relevant in the context of breast
cancer.
Traditionally, the site of origin has been one of the primary
features with which to classify breast cancers [23-25]. The full
transcriptional profiles of our cell line panel show this charac-
teristic split between basal and luminal subtypes [43], which
we could largely recapitulate in our construction of the initial
states (Figure 2). Here, we have shown that ErbB/MAPK sig-
naling systematically varies across our panel of cell lines. Spe-
cifically, we found that the cell line networks could be
classified into three groups (Figure 4). The basal and luminal
network groups reflect the split we observed in the compo-
nents of the initial state, while the third mixed group is largely
defined by signaling related to Src. Src acts as a well-con-
nected signaling hub, so it is particularly important in shap-
ing network architecture. It also interacts with several key
proteins in the MAPK cascade, including EgfR and its targets,
Erk, and Cdc42 [71,72]. Src has been studied as a therapeutic
Table 4
Summary of signaling modules
Number of rules Key component(s) Summary of key events
1 1 Pi3k, ErbB4 ErbB4 activation of Pi3k
2 1 Snca Pyk2 activation of Snca
3 1 Caml, Rsk Rsk activation of Caml
4 1 Stat3 Stat3 activation by EgfR
5 1 Irs, Pi3k Irs activation of Pi3k
6 1 Rela Formation of Ikba, Nfkb1, Rela complex
7 2 Pik3ca-mut Akt signaling through Pi3k mutant
8 2 Mef2c Camk activation of Mef2c
9 2 IL11R, Jak IL11R activation of Jak
10 2 Elmo, Rac1 Elmo activation of Rac1
11 2 Abi1, Pir121 Wave1 activation dependent on Abi1 and Pir121
12 3 Mylk Mylk activation of Mlc
13 3 RhoB RhoB activation
14 3 EsR1, Bcat EsR1 activation by Rsk; Bcat activation
15 3 Fos Fos activation by Erk
16 3 Bcat Activation and degradation of Bcat
17 4 Cav1, UpaR Integrin/Cav1 activation of Shc; UpaR activation
18 5 Pten, Kras, Pik3ca Mutation rules
19 5 ErbB4 ErbB4 activation of ErbB2, Shc; Grb2 relocation
20 6 PrlR PrlR signaling
21 7 Irs1 Irs1 activation; Grb2 translocation
22 8 Pi3k Eight ways to activate Pi3k
23 12 RhoB RhoB activation of first-order effectors
24 12 Cbl Cbl-related signaling, including Rap1a, Crk, Dock
25 14 Src Src-related signaling, including Fak, Pax, Cas
26 15 EgfR First-order EgfR interactions including ErbB2, Grb2, Cbl
27 16 Efna1 EphA2/Efna1 signaling; Integrin deactivation by EphA2
28 27 ErbB3 ErbB3 activation by Nrg1 and ErbB2; ErbB3 activation of Shc
29 32 EgfR, Src Src-dependent activation of EgfR; Cdc42 signaling; activation of Src effectors
30 76 Src, Rac1-GTP Rac1 signaling; MAPK activationhttp://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.10
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target in a wide range of cancers, including cancers of the
breast, lung and pancreas [73,74].
The basal and luminal networks could be well-differentiated
by the RhoB signaling module, which is present in the luminal
cell lines and absent from the more aggressive basal cell lines
(Figure 4). A number of reports have indicated that loss of
RhoB expression is frequently associated with cancer pro-
gression [58]. Furthermore, suppression of RhoB is a critical
step leading to transformation in a variety of cancers, includ-
ing those of the lung and cervix [75]. These observations bol-
ster the idea that modulation of the RhoB pathway may serve
as a useful therapy in the basal cell lines. Among the basal cell
line networks, the Cav1/Integrin signaling module was pri-
marily found in the most aggressive basal B cell lines. In
accordance with this, Cav1 has been shown to have a role in
carcinogenesis, though its mechanism may vary with cancer
type [76,77].
Pak1 impacts signaling along the MAPK cascade
Through an analysis of our breast cancer network models, we
identified Pak1 as a putative differential regulator of the
MAPK cascade in our cell lines. Pak1, a serine/threonine
kinase, has long been studied as a regulator of cytoskeletal
remodeling and cell motility [78,79], but more recently has
been shown to regulate both proliferation [80] and apoptosis
[81]. The Pak family of proteins has been implicated in a vari-
ety of cancers, including those of the breast [80,82,83]. In
particular, Pak1 hyperactivation has been shown to cause
mammary-gland tumors in mice [84].
Across our panel of cell lines, Pak1 is differentially expressed
at the copy number, transcript and protein levels (Figure 6).
The finding of elevated Pak1 expression in some of our cell
lines mirrors the observation that Pak1 is sometimes upregu-
lated in breast tumors [80]. The correlation between Pak1
and phospho-Mek1 levels (Figure 6c) suggests that across the
cell lines, Pak1 differentially modulates activation of the
MAPK cascade. Although statistically significant, this correla-
tion was not perfect: high Pak1 levels are always associated
with high phospho-Mek1 levels, while a more variable rela-
tionship emerges when Pak1 is low. This observation implies
that when Pak1 levels are high, it dominates the regulation of
phospho-Mek1, whereas at low Pak1 levels, alternate proteins
must serve as the principle regulator of phospho-Mek1. For
example, Ksr1 (Kinase suppressor of ras-1) and Spry (sprouty
homolog, antagonist of FGF signaling) are both involved in
regulation of the MAPK cascade, and may be particularly
important in the cell lines that express Pak1 at low levels
[85,86]. Based on this finding, we hypothesized that the lumi-
nal cell lines that over-express Pak1 would be particularly
sensitive to Mek inhibition. Indeed, the Pak1 over-expressing
cell lines were significantly more sensitive to three Mek inhib-
itors than the non-Pak1 over-expressing cell lines (Figure 7).
The observation that all three drugs showed the same pattern
indicates that the inhibition is quite robust and not due to off-
target effects. These results indicate that Pak1 over-expres-
sion may be a useful clinical marker to determine which
patient populations may be sensitive to Mek inhibitors.
Conclusions
Breast cancer is a remarkably heterogeneous disease that
results from the accumulation of various genetic defects. We
were interested in identifying signaling subnetworks that may
be particularly important in generating oncogenic pheno-
types. To address this, we generated a discrete, static network
model for a panel of 30 breast cancer cell lines. The resultant
network models were highly variable: of the protein interac-
tions predicted to occur, over half of them varied across the
cell lines. We searched for active subnetworks by clustering
the network features of our models. This clustering yielded
three main groups of cell lines, a basal group, a luminal group,
and a third mixed group composed of both basal and luminal
cell lines. In addition, we identified several network modules
active in specific subsets of the cell lines. One signaling mod-
ule implicated Pak1 as a key regulator of the Raf-Mek-Erk
pathway in the cell lines that over-express it. Based on this
observation, we hypothesized that luminal cell lines that
over-express Pak1 would be particularly responsive to Mek
inhibition. In support of this idea, we found that among lumi-
nal cell lines, the over-expression of Pak1 was indeed signifi-
cantly associated with sensitivity to three Mek inhibitors. All
together, these results indicate the utility of symbolic systems
modeling for the identification of key cell signaling events in
the context of cancer.
Materials and methods
Cell lines
The complete panel contains 51 breast cancer cell lines that
have been previously described [43]. We assembled our panel
of breast cancer cell lines from the ATCC and the laboratories
Cav1/Integrin signaling module is present in basal cell lines Figure 5
Cav1/Integrin signaling module is present in basal cell lines. (a) Signaling 
module. Cav1, Integrin and Fyn interact to activate SHC, which leads to 
activation of the MAPK cascade. (b, c) Distribution of Cav1 transcript (b) 
and protein (c) levels across the cell lines. Both datasets show a bimodal 
distribution of Cav1.
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of Drs Steve Ethier and Adi Gazdar. All cell lines have been
carefully maintained in culture, and we have stored stocks of
the earliest-passage cells. We assure quality control by careful
analysis of morphology, growth rates, gene expression and
protein levels over time. All extracts were made from subcon-
fluent cells in the exponential phase of growth in full media.
Information about biological characteristics and culture con-
ditions is available elsewhere [87]. We generated network
models for the 30 well-characterized cell lines with the com-
plete datasets described below.
Protein abundance data
We measured the abundance of 25 proteins associated with
ErbB/MAPK signaling in our network model. These abun-
dances were assayed and quantified as previously described
[43]. Briefly, proteins were measured by western blots of cells
lysed in 1% Nonidet-P40, 50 mM HEPES (pH 7.5), 150 mM
NaCl, 25 mM b-glycerophosphate, 25 mM NaF, 5 mM EGTA,
1 mM EDTA, 15 mM pyrophosphate, 2 mM sodium
orthovanadate, 10 mM sodium molybdate, leupeptin (10 mg/
ml), aprotinin (10 mg/ml), and 1 mM phenylmethylsulphonyl
fluoride (PMSF).
Pak1 is a critical component of the MAPK cascade in our network models Figure 6
Pak1 is a critical component of the MAPK cascade in our network models. (a) Subnet shows that Pak1 leads directly to activation of Raf, Mek and Erk. (b) 
Distribution of Pak1 transcript levels used in construction of the initial states. Pak1 yields two clusters: a lower 'absent' cluster centered at -0.26 and an 
upper 'present' cluster centered at 2.16. (c) Pak1 protein and transcript levels are correlated. Protein abundance is plotted on the x-axis; transcript data 
(log2 scale) is plotted along the y-axis. The line represents the least-squares fit to the data. (d) Copy number profiles for the region around the Pak1 
amplicon on chromosome 11. The vertical lines represent the locations of CCND1 (69 Mb) and Pak1 (76 Mb). (e) Pak1 protein levels are correlated with 
percent phospho-Mek1. Each dot represents data from one cell line. The line represents the least-squares fit to the data.
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We quantified protein levels by measuring the emitted chemi-
luminescence or infrared radiation recorded from labeled
antibodies using Scion Image [88] or Odyssey software [89].
For each protein, the blots were made for 4 sets of 11 cell lines,
where each set included the same pair (SKBR3 and MCF12A)
to permit intensity normalization across sets. We performed
a basic multiplicative normalization by fitting a linear mixed-
effects model to log intensity values, and adjusted within each
set to equalize the log intensities of the pair of reference cell
lines across the sets.
Transcriptional profiles
Total RNA was prepared from samples using Trizol reagent
(GIBCO BRL Life Technologies; Carlsbad, CA, USA) and
quality was assessed on the Agilent Bioanalyser 2100. Prepa-
ration of in vitro transcription products, oligonucleotide
array hybridization, and scanning were performed according
to Affymetrix (Santa Clara, CA, USA) protocols. In brief, 5 g
of total RNA from each breast cancer cell line and T7-linked
oligo-dT primers were used for first-strand cDNA synthesis.
In vitro transcription reactions were performed to generate
biotinylated cRNA targets, which were chemically frag-
m e n t e d  a t  9 5 ° C  f o r  3 5  m i n u tes. Fragmented biotinylated
cRNA (10 g) was hybridized at 45°C for 16 h to an Affymetrix
high-density oligonucleotide array human HG-U133A chip.
The arrays were washed and stained with streptavidin-phyco-
erythrin (final concentration 10 g/ml). Signal amplification
was performed using a biotinylated anti-streptavidin anti-
body. The array was scanned according to the manufacturer's
instructions (2001 Affymetrix Genechip Technical Manual).
Scanned images were inspected for the presence of obvious
defects (artifacts or scratches) on the array. Defective chips
were excluded, and the sample was reanalyzed.
We generated probe set based gene expression measurements
from quantified Affymetrix image files with the RMA algo-
rithm [90] from the BioConductor tools suite [91] and anno-
tated with Unigene annotations from the July 2003 mapping
of the human genome [92]. All 51 CEL files were analyzed
simultaneously, yielding a data matrix of probe sets by cell
lines in which each value is the calculated log abundance of
each gene probe set for each cell line. Gene expression values
were centered by subtracting the mean value of each probe set
across the cell line set from each measured value.
Mutation data
We searched the Sanger Catalogue Of Somatic Mutations In
Cancer (COSMIC) website for reported mutations in our cell
lines [46]. We incorporated mutations to Kras, Pten and
Pik3ca into our models through the construction of rules that
reflect the functional impact of each mutation.
Copy number profiles
We measured copy number profiles with molecular inversion
probes (MIPs). The MIP assay was performed as previously
described [93]. Briefly, test DNA samples were diluted to 16
ng/ml. All DNA quantification was done using PicoGreen
dsDNA Assay Kit (P7589; Molecular Probes/Invitrogen,
Carlsbad, CA, USA). We used 96- or 384-well plates whenever
possible to reduce variation. For day 1 overnight annealing,
4.7 l of DNA samples (75 ng total), 0.75 l of Buffer A, 1.1 l
of the 53 K probe pool (200 amol/l/probe) and 0.045 l of
Enzyme A were mixed well in a 384-well plate on ice. The
reaction was incubated at 20°C for 4 minutes, 95°C for 5 min-
utes, then 58°C overnight. On day 2, 13 l of Buffer A was
added to each well with 1.25 l of Gapfill Enzyme mix, then 9
l of this was put in each of two wells in a 96-well plate. MIP
probes were circularized with 4 l of dinucleotide (dATP with
dTTP, dCTP with dGTP) and mixed at 58°C for 10 minutes.
The uncircularized probes and genomic DNA were eliminated
by addition of 4 l of Exonuclease Mix and incubation at 37°C
for 15 minutes, followed by heat-killing of enzymes. The cir-
cularized probes were linearized by the addition of Cleavage
Enzyme Mix at 37°C for 15 minutes, then subjected to univer-
sal primer amplification for 18 cycles at 95°C for 20 s, 64°C
for 40 s, and 72°C for 10 s. For the labeling reaction, the prod-
uct was further amplified with the label primers for 10 cycles,
and then subjected to cleavage by Digest Enzyme Mix at 37°C
for 2 h. To hybridize, the cleaved MIP products were mixed
with hybridization cocktail, denatured and hybridized to 70 K
Universal Taq arrays at 39°C for 16 h (two arrays per sample).
The overnight hybridized arrays were washed on GeneChip®
Fluidics Station FS450 and stained by streptavidin-phyco-
erythrin at 5 ng/ml (Invitrogen). Copy number estimation
was obtained from the hybridization signals as previously
described [93].
Pak1 over-expression predicts responsiveness to Mek inhibitors Figure 7
Pak1 over-expression predicts responsiveness to Mek inhibitors. Each pair 
of boxplots represents the average GI50 for luminal cell lines that over-
express Pak1 (Pak1-high, blue) and those that express it at normal levels 
(Pak1-low, red). Within each box, the line represents the median; upper 
and lower boundaries represent the first and third quartiles, respectively. 
The vertical lines extend to +/- 1.5 IQR. For all three drugs, Pak1-high cell 
lines are significantly more sensitive than Pak1-low cell lines.
4
5
6
7
8
CI-1040 GSK1120212 UO126
-log10 GI50
Pak1 high
Pak1 lowhttp://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.13
Genome Biology 2009, 10:R31
We filtered the dataset to eliminate MIP probes missing from
more than 5% of the samples. We used the previously
described amplicon boundaries to compute average copy
number across all the probes in the Pak1 and CCND1 ampli-
cons [60]. We defined high-level amplification as Median
copy number + (3 × Interquartile range), each computed
across all amplicons and cell lines.
Quantitative analysis of Mek
We used high-resolution capillary isoelectric focusing tech-
nology to quantify the abundance of individual phosphoforms
and isoforms of Mek. We used Mek1 (Upstate Biotechnology,
Lake Placid, NY, USA) and Mek2 (Cell Signaling, Danvers,
MA, USA) antibodies for this assay, which has been described
in detail elsewhere [94].
Cell growth inhibition assay and data analysis
Cells were plated at proper density in 96-well plates such that
they would remain in log growth at the end of assay time. The
cells were allowed to attach overnight before being exposed to
Mek inhibitor CI-1040, UO126 or GSK1120212 for 72 h. Drugs
were dissolved in dimethyl sulfoxide (DMSO) as 10 mM stock,
and a set of 9 doses in 1:5 serial dilution was added in tripli-
cate wells. The final DMSO concentration in the treated well
was 0.3% or less. The cell growth was determined using Cell
Titer Glo assay (CellTiter-Glo Luminescent Cell Viability
Assay; Promega, Madison, WI, USA), with slight modification
from the manufacturer's protocol at day 0 (time when drug
was added) and day 3 of drug exposure. Briefly, Cell Titer Glo
reagent was diluted with phosphate-buffered saline (1:1 v:v)
and the culture media was removed from the 96-well plate
prior to adding 50 l per well of the diluted Cell Titer Glo rea-
gent. Luminescence from the assay was recorded using BIO-
TEK FLx800.
D a t a  c a l c u l a t i o n s  w e r e  m a de according to the method
described by the NCI/NIH DTP Human Tumor Cell Line
Screen Process [95] and as previously described [96]. The
percent growth curve is calculated as [(T - T0)/(C - T0)] × 100,
where T0 is the cell count at day 0, C is the vehicle control (for
example 0.3% DMSO without drug) cell count at day 3, and T
is the cell count at the test concentration. We calculate the
GI50 and total growth inhibition (TGI) values after 72 h drug
exposure. The GI50 is the drug concentration that results in
50% growth inhibition; the TGI is the drug concentration that
yields 100% growth inhibition.
Pathway Logic modeling system
Pathway Logic [97] is a system for building discrete, logical
models of biological systems [35,36]. The construction of a
Pathway Logic model requires two key elements: a set of rules
and an initial state. Each rule represents a statement of a pre-
cisely defined biological transformation or biochemical reac-
tion. For example, the rule below describes the activation of
the ErbB2 receptor by activated EgfR:
rl[793.ErbB2.on]:
{CLm | clm [EgfR - act] ErbB2}
= >
{CLm | clm [EgfR - act] [ErbB2 - act]}.
The first term on each line represents a cellular location. In
this case, CLm indicates that EgfR and ErbB2 are located in
the cell membrane. A reaction will occur ('fire') only if the
components are located in the specified cellular compart-
ment. Most rules in our database describe changes to the state
of a protein, such as activation, exchange of GDP for GTP, or
translocation to a different cellular compartment. In total, the
relevant rule database contains 396 rules, all of which have
been individually curated from primary literature sources.
The initial state specifies the model components present in a
cell, as well as their locations. We created the initial states for
each network model from a set of 286 components. Models
are generated by 'rewrites.' In a simple rewrite, the initial
state is presented to the rules. Whenever the state meets the
conditions required by a rule input, the state is adjusted in
accordance with the rule. The new state is then presented to
the rules and more adjustments are made. This iterative proc-
ess continues until either no further alterations can be made,
or a user-defined condition is reached. We visualize the result
of these rewrites as a Petri net, a directed bipartite graph that
contains places, transitions, and directed arcs that connect
the places and transitions [98]. In Petri net models of cell sig-
naling, places represent proteins and transitions represent
chemical reactions. Petri nets are a useful representation
because they closely resemble hand-drawn cartoon models of
cellular signaling pathways.
Data discretization
We discretized the protein and transcript data in order to
determine which components were present in (or absent
from) the initial state of each cell line network model. Con-
ceptually, the idea was to analyze the expression data for each
protein in the initial state in order to decide if it showed dif-
ferential expression across the panel of cell lines. Proteins
that showed a highly variable expression pattern across the
panel of cell lines were considered present in some cell lines
and absent from others. Our approach to discretization and
creation of the initial states was quite conservative. That is,
we did not omit a component from the initial state unless
there was strong evidence that it is absent from a particular
cell line. We chose a conservative approach because in dis-
crete networks such as these, errant omission of a component
from the initial state can lead to significant effects on the
structure of the network, in the form of truncated signaling
pathways (Figure 1b).http://genomebiology.com/2009/10/3/R31 Genome Biology 2009,     Volume 10, Issue 3, Article R31       Heiser et al. R31.14
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We developed the following discretization method and
applied it to both the protein and transcript data. First, for
each gene or protein, we used PAM clustering and a mean
split silhouette (MSS) statistic to determine whether the log-
transformed expression values are best represented as 1, 2 or
3 groups of cell lines [99]. We searched for one, two or three
groups because the distributions of expression values appear
unimodal (that is, one group; Figure 1c), bimodal (that is, two
groups; Figure 1d), or tri-modal (Figure 1e). We used the MSS
statistic for three reasons: first, it can be used to classify the
expression values as a single group, whereas most algorithms
(for example, k-means) require a minimum of two groups;
second, it accurately classified both one-tailed and two-tailed
distributions; and finally, because it could identify small clus-
ters in the data.
Next, for genes that clustered into two or three groups, we
compared the mean expression levels of the groups. If the
expression levels between the highest and lowest group dif-
fered by less than a four-fold change, we collapsed the groups
together. This ensured that expression differences between
the groups were great enough to be meaningful. We assigned
proteins to the initial states in the following way. If a single
group best described the distribution of expression values,
the protein was considered present in all the cell lines. For
distributions that yielded more than one group, the protein
was considered absent from the initial state of the cell lines
with the lowest mean expression; the protein was present in
the initial state of cell lines in the highest group(s). We con-
sidered the protein present in the two clusters with highest
mean expression in order to avoid erroneous omissions from
the initial state of cell lines in the middle expression group.
Finally, if we had no data available from which to estimate the
initial state, we considered the protein present in all cell lines.
For model components that had both transcript and protein
data available, we used the clustered protein (rather than
transcript) data to populate the model. To ensure that we
made the most robust initial state assignments possible, we
used data from as many of the 51 cell lines for the discretiza-
tion step, even if we ultimately did not create a network model
for the cell line. We performed the analyses above in R with
the hopach package, available as part of the BioConductor
tools suite [100].
Analysis of network topology
We used the following method to compare the networks.
First, we decomposed each network into a list of all the com-
ponents and rules contained within it. This list describes all
the state changes (for example, phosphorylation) and reac-
tions in each network. We clustered the network features with
PAM and an MSS, which searched for the optimal number of
clusters, up to a maximum of 40. Each cluster can be consid-
ered a unique 'signaling module' that represents a small por-
tion of the total network. We compared the presence or
absence of these signaling modules across the panel of cell
lines.
Hierarchical clustering and data visualization
The discretized data used to populate the initial states were
hierarchically clustered using an average linkage algorithm
and a Pearson correlation for the distance measure [53]. We
also used this algorithm to cluster the cell line network mod-
els. We used Java TreeView to visualize the clustered data in
Figures 2 and 4[101].
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